Berthel Fisher & Co Financial Services’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-67
Closed -$3.81K – 2530
2026
Q2
$3.81K Hold
67
– – ﹤0.01% 1867
2026
Q1
$1.99K Sell
67
-2
-3% -$60 ﹤0.01% 2094
2025
Q4
$2.64K Buy
+69
New +$2.24K ﹤0.01% 2071

Other funds holding TVTX

Berthel Fisher & Co Financial Services's TVTX Position: Q3 2026 in Review

Berthel Fisher & Co Financial Services sold out of Travere Therapeutics (TVTX) in Q3 2026, closing a stake of 67 shares — an estimated $3.81K sold.

Berthel Fisher & Co Financial Services first reported a position in TVTX in Q4 2025 and held it in 3 quarters. The position peaked at $3.81K in Q2 2026. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • Berthel Fisher & Co Financial Services reported no remaining Travere Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Berthel Fisher & Co Financial Services sold 67 Travere Therapeutics shares in Q3 2026, an estimated $3.81K.
  • Berthel Fisher & Co Financial Services first reported a position in Travere Therapeutics in Q4 2025 and held it in 3 quarters.
  • Berthel Fisher & Co Financial Services's Travere Therapeutics position peaked at $3.81K in Q2 2026.
  • 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Berthel Fisher & Co Financial Services's 13F filing for Q3 2026, filed 13 Nov 2026.